MLICM
NGNE icon

Metropolitan Life Insurance Company (MetLife)’s Neurogene NGNE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-235
Closed -$34K – 2814
2021
Q3 		$34K Sell
235
-259
-52% -$39.7K ﹤0.01% 2795
2021
Q2 		$91.1K Hold
494
– – ﹤0.01% 2615
2021
Q1 		$122K Sell
494
-16
-3% -$4.09K ﹤0.01% 2335
2020
Q4 		$144K Hold
510
– – ﹤0.01% 2158
2020
Q3 		$122K Hold
510
– – ﹤0.01% 2099
2020
Q2 		$169K Buy
+510
New +$133K ﹤0.01% 1916

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NGNE Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Neurogene (NGNE) in Q4 2021, closing a stake of 235 shares — an estimated $34K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NGNE in Q2 2020 and held it in 6 quarters. The position peaked at $169K in Q2 2020. 80 funds tracked by Wall St. Rank hold NGNE as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Neurogene position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 235 Neurogene shares in Q4 2021, an estimated $34K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Neurogene in Q2 2020 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Neurogene position peaked at $169K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held Neurogene as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.